Today’s Promega Connections blog is written by guest blogger Tori Sheldon, North America Marketing and Events Coordinator.
It is crazy to think how quickly the months fly by. It feels like yesterday I was watching the ball drop as 2017 turned to 2018. Now it is almost March, when Wisconsin starts to emerge from the cold winter. March also happens to be National Optimism Month.
As I think about optimism, I am reminded of one of the core values that guide interpersonal relationships at Promega: “look for the good, with discernment”. The spirit of this value is to remember that deep down everyone is trying to come from a positive place and that even though we may not always agree with each other it is an opportunity for further discussion and collaboration.
Today’s blog post is written by guest blogger, Josh Agate, Manager, Global CRM.
Adventure is relative. Most people are looking for new adventures in life, and those can range from planning where to go on vacation to starting a new job. What each person looks for in an adventure and the level of thrill they seek is different. When I learned that Promega had awarded me a trip to a destination of my choice with my family for my job performance, I was excited to plan this new adventure with my wife and two daughters (ages 4 and 6). We decided on a trip to Belize.
The trip required two commercial flights, followed by a puddle jumper flight (with hand-written boarding passes), and a 30 minute boat ride before we arrived at our hotel on the island of Ambergris Caye. This island, off the northern coast of Belize, would provide the backdrop for our family’s greatest adventure to date. The trip to get to the island wasn’t tedious travel for them; it was a wild ride that included a plane that held 12 people, flying over crystal clear waters and a boat trip, where our hair flew wildly as we were sprayed with ocean mist. Continue reading “Adventure in Belize”
Recently, I had the opportunity to attend a fascinating symposium held at Promega featuring conservationist Steward Brand, where he described some of the projects developed by his foundation, Revive & Restore.
The organization’s mission is to apply emerging biotechnology techniques to endangered and extinct species with the intent to increase genetic diversity, provide disease resistance and facilitate adaptation to changing climates. Although the overall message of enhancing biodiversity through the application of new genetic technology was inspiring, the project that resonated most for me was related to the plight of horseshoe crabs.
Horseshoe crabs, often referred to as living fossils, include four extant species with origins dating back about 450 million years. Although they look like crabs, they belong to their own subphylum and are more closely related to spiders. When horseshoe crabs spawn, they leave their usual habitat on the ocean floor and migrate to shore in large numbers. As a result, they have been exploited for bait and fertilizer for decades.
Enter endotoxins, an indicator for bacterial contamination in biologicals, drugs and medical devices. U.S. Food & Drug Administration regulations dictate that finished products be tested for the presence of endotoxins. These pyrogenic compounds, found in the cell wall of Gram-negative bacteria, can cause fever and affect a wide range of biological activity, possibly leading to aseptic shock and death. The most common method for testing is the gel clot and Limulus Amebocyte Lysate (LAL) Test.
I first learned about the LAL test during graduate school, where it was presented as a ubiquitous and standard requirement for testing bacterial contamination in injectable drugs. I remember being fascinated that horseshoe crabs (Limulus sp.), contain a substance that could be used to detect endotoxins. Although the instructors mentioned the need to collect blood from horseshoe crabs in order to produce the test, the method or scale of this harvest wasn’t discussed, nor were the true costs of using this method of endotoxin testing.
The LAL test has served as a faster, more inexpensive replacement for the rabbit pyrogens test for the past 35 years. Every year during mating season horseshoe crabs move to shallow water, where they are removed in huge numbers. (To get an idea of scale for the harvest and read a much more comprehensive investigation of the issue, check out this article in The Atlantic, which features an archive photo of Delaware Bay horseshoe crab harvest from 1928—for fertilizer, not pharmaceutical testing.)
After collection, the crabs end up in a lab where up to 30% of their blood is drained from a needle stuck in tissue around their heart. The LAL is extracted from the blood and can yield a product worth up to $15,000/quart. In order to avoid recollection, the crabs are returned to the ocean far from the shore where they were collected a few days before. Although it’s estimated that only 10-30% of these crabs die as a result of the process, there are indications that the horseshoe crab population and their ecosystems are impacted in other ways.
Researchers at the University of New Hampshire and Plymouth State University used accelerometers attached to recently bled female horseshoe crabs to test the hypothesis that harvesting for LAL was affecting their ability to spawn. While the research supported previous estimates with a death rate of 18%, females were found to be less likely to mate after being bled.
During his talk, Brand shared results from a study still in review that confirm the effect of over-harvesting Limulus on the survival of long distance migratory shorebirds. These birds synchronize their migration with horseshoe crab spawning, which provides a needed feast of eggs before the homestretch of their journey. Along with other ecosystem threats from climate change, the accelerated decline in the horseshoe crab population and dependency of migratory birds will likely to lead to a devastating ecological domino effect.
Fortunately, a synthetic alternative to LAL, recombinant factor C (rFC), has been available for nearly 20 years. Alas, there has been no significant shift by pharmaceutical companies away from the test based on horseshoe crab blood. rFC was patented and licensed to one company, Lonza, which Brand posited as one reason for the reluctance of drug companies to adopt its use.
Obviously, relying on one source for an essential testing reagent with no competition to temper cost is quite unattractive. But that argument has less bearing now that the patent is scheduled to expire in a few months, opening the door for additional manufacturers and creating an economic incentive for switching to the synthetic test.
Another reason may be that implementing a new test would require additional resources to validate the synthetic test for products that are already being tested with the LAL. Since the LAL has been specified in FDA guidance documents on endotoxin testing for decades, quality standards for existing products are based on the LAL, limiting momentum to change.
If both tests offered the same benefits, these arguments would make sense; however, research by one of the discoverers of rFC, Jeak Ling Ding of the National University of Singapore, shows that in many respects rFC is more efficacious than LAL. Since the raw material for the LAL test depends on an organism, there is seasonal variation in the components of the processed blood that must be taken into account. The reaction of the LAL also depends on a cascade of multiple compounds that can be affected by temperature, pH and proteins—leaving the test vulnerable to false positive results.
Although Eli Lilly is the only pharmaceutical company to date to use rFC in place of LAL, It seems the tide may be turning. According to Brand, others are interested in making the transition. It seems foolish not to, given the source for LAL shows signs of dwindling due to overexploitation. Perhaps pharmaceutical companies are beginning to see the value of a “slower/better” philosophy (the cornerstone of the Long Now Foundation, another brainchild of Brand’s), rather than “faster/cheaper.” I have certainly gained a new perspective on endotoxin testing and a deep appreciation for the work of Brand and his foundation.
Does your organization use the LAL test? What is preventing you from switching to the synthetic alternative? Let us know!
The researchers completed an analysis revealing that patient information materials had an average readability at a high school level, while the average patient reads at a fourth-grade level. These findings inspired the researchers to conduct a study in which they enlisted the help of elementary students to revise the content of the patient literature after giving them a short lesson on the material.
The resulting content did not provide more effective ways to communicate indications, pre- and post-op care, risks or procedures—that wasn’t really the point. Instead, the study underscores the important connection between patient literacy and health outcomes. More specifically, a lack of health literacy is correlated with poor outcomes and increased healthcare costs, prompting action from the US Department of Health & Human Services.
While healthcare information can be complex and full of specific medical terminology, I recognized that a lot of the technical and marketing information we create for our products at Promega has similar features. Wouldn’t it be interesting to find out how descriptions of some of our biggest technologies translate through the eyes and mouths of children?
After enlisting some help from my colleagues, I was able to catch a glimpse of how our complex technologies are understood by the little people in our lives. The parents and I explained a technology and then had our child provide a description or drawing of what they understood. Continue reading “Biotechnology From the Mouths of Babes”
We invite you to travel with Bettina Bazzini-Lapin, Scientific Client Specialist, who was awarded a Promega Travel Award for sales performance and used her award to travel to Croatia and Italy. In this blog, she describes her travels.
Croatia is an Eastern European country that sits on the Adriatic Sea directly across from Italy. It has more than one thousand islands, and a third of the country is covered by forest. It is known for its beautiful Dalmatian coast line. One of the main sites for travelers to visit is the coastal city of Dubrovnik, known as the Pearl of the Adriatic. This is where my adventure began. Continue reading “Promega Travel Award Blog: An Excursion to Croatia”
Every year around the beginning of December, a magical transformation begins in Promega offices in Madison and around the world. In Madison, even as our own Promega cookie elf is busily baking the last of her Holiday treats, employees are donning their own elf hats and bedecking our halls and cubes with their own form of Holiday magic.
Different teams put different spins on their decorating; from an all-out coordinated effort, to individualized decorations that reflect the personality of the decorator . It is fun to see how different areas get into the Holiday spirit. Continue reading “Deck the Halls…and Cubes…and Desks”
Working at a manufacturing company like Promega means quite a few people here spend their days obsessing (rightly so) over things like bulk production, product finishing and quality assurance. As the holiday season approaches, however, many Promega Madison employees also begin obsessing (rightly so) over some extremely important manufacturing going on in Elaine York’s Wisconsin kitchen.
Elaine is married to Chuck York, Vice President of Manufacturing Operations at Promega. Each Christmas, she bakes thousands (yes, thousand with an “s”) of made-from-scratch Christmas cookies of every variety, artfully arranged on around 50 platters, which Chuck then brings to work to share with his lucky coworkers.
University of Wisconsin-Madison undergraduate Celia Glime didn’t think she was creating a design for the 2017 Promega holiday card while doing lab work last winter for her introductory Chemistry 104 class. She was simply doing her homework.
Celia explains she was studying the progression of three chemical reactions in test tubes when she decided to take out her smartphone and snap some photos to use for her lab report. (Bonus points if you can tell from the photo what’s causing each reaction. Answers below.)
“I ended up creating an art project instead,” she says.
Celia, who at the time was considering a major in genetics and a minor in visual art, had been keeping an eye out for instances of science in real life. Her mentor on campus, Professor Ahna Skop, a geneticist and artist herself, had recently told Celia about the annual University of Wisconsin Cool Science Image Contest, sponsored by Promega. The contest aims to bring together the worlds of science and art by recognizing the technical and creative skills required to capture images or video that document science or nature.
This blog post is contributed by guest blogger Diana Clark, Benefits Manager, Promega Corporation
November is National Family Caregivers Month, first proclaimed by President Clinton in 1997, the proclamation has been renewed by every U.S. President since. When President Obama proclaimed this designation in 2012, he commented, “The unselfish devotion of family caregivers affirms the importance of respecting the dignity of life in all stages and underscores the importance of the family unit.”
Hearing these words, I felt even prouder to be a part of the Promega family. You see, we are already in the process of rolling out Caregiver Leave for 2018. Caregiver Leave will provide Promega employees with an additional two weeks of paid time off annually to care for a sick parent, spouse or child, or to welcome a new child into their family via birth, adoption or foster placement. Continue reading “Honoring Caregivers”
When I was in grad school and pictured what a role in industry would look like, the first thing that came to my mind was a Research and Development (R&D) Scientist. My life as a grad student and as a postdoc revolved around benchwork, so that must be the case in industry too, right?
It really wasn’t until I started working at Promega that this image of a scientist in industry was completely turned upside down (in a good way). Here are some roles that a scientist can assume at Promega: Senior Scientist, Research Scientist, R&D Group Leader, Production Scientist, Technical Services Scientist, Product Manager, Strategic Marketing Manager, Client Support Specialist, Client Support Consultant, Clinical Technical Consultant, Field Support Scientist, Applications Scientist, Scientific Instructional Designer. The list can probably go on for a while, but it makes the point that there are a variety of interesting positions for scientists in the biotech industry. Continue reading “BioTech Scientists through a Different Lens”